U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362927) titled 'Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients' on Jan. 15.
Brief Summary: The goal of this study is to evaluate the safety and efficacy of LX111 treatment of DME. This study will enroll participants aged >= 18 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its safety and efficacy.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Diabetic Macular Edema (DME)
Intervention:
GENETIC: LX111 Injection
LX111 is an rAAV gene therapy vector carrying a coding sequence for VEGF-trap.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai General Hos...